Výsledky vyhledávání - "Stephen Langman"

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors

Autor: Jörg Kleeff, Moritz N. Wente, Helmut Friess, Peter Cheverton, Stephen Langman, Markus W. Büchler, Jantien Wanders

Publikováno v: Investigational New Drugs. 23:339-347

Background: DE-310 is composed of the topoisomerase-I-inhibitor DX-8951 (exatecan) and a biodegradable macromolecular carrier, which are covalently linked by a peptidyl spacer. In pre-clinical studies, high levels and prolonged retention of conjugate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69d2a075986c54824379d92c3eaffff3
https://doi.org/10.1007/s10637-005-1442-2

Zobrazit plný text záznamu

An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee

Autor: John P. Huggins, Stephen Langman, Tim Young, Trevor S. Smart, Louise Taylor

Publikováno v: PainReferences. 153(9)

The effect of PF-04457845, a potent and selective fatty acid amide hydrolase-1 (FAAH1) inhibitor, on pain due to osteoarthritis of the knee was investigated in a randomised placebo and active-controlled clinical trial. The trial involved 2 periods (s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d00ed97187a469e9abe0c99e3d402729
https://pubmed.ncbi.nlm.nih.gov/22785079

Zobrazit plný text záznamu

Akademický článek

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.

Autor: Moritz N. Wente, Markus W. Bchler, Jantien Wanders, Peter Cheverton, Stephen Langman, Helmut Friess

Publikováno v: Investigational New Drugs; Aug2005, Vol. 23 Issue 4, p339-347, 9p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání